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PURPOSE. We aimed to determine differentially expressed genes relevant to orbital
inflammation and orbital fat expansion in thyroid orbitopathy (TO) using microarray gene
profiling in a case-control study.
METHODS. Human orbital adipose samples were obtained from individuals with active TO (n ¼
12), inactive TO (n ¼ 21), and normal controls (n ¼ 21). Gene expression profiles were
examined using microarray analysis and were compared between active and inactive TO, and
between active TO and normal controls. Top ranked differentially expressed genes were
validated by real-time RT-PCR in an additional eight active TO, 13 inactive TO, and 11 normal
controls and correlated with gene set enrichment analysis (GSEA) and molecular pathways
analysis.
RESULTS. Seven hundred twenty-one probes (683 genes) and 806 probes (735 genes) were
significantly differentially expressed in comparing active to inactive TO and in comparing
active TO to healthy controls, respectively. All selected genes were confirmed to be
differentially expressed by real-time RT-PCR. Multiple top ranked genes in active versus
inactive TO comparison are overrepresented by immune and inflammatory response genes.
They include defensins (DEFA1, DEFA1B, DEFA3), which were overexpressed by 3.05- to
4.14-fold and TIMD4 by 4.20-fold. Markers for adipogenesis were overexpressed including
SCD, FADS1, and SCDP1. Gene set enrichment analysis revealed dysregulation of epigenetic
signatures, T-cell activation, Th1 differentiation, defensin pathway, cell adhesion, cytoskeleton
organization, apoptosis, cell cycling, and lipid metabolism in active TO.
CONCLUSIONS. Active TO is characterized by upregulation of genes involved in cell-mediated
immune, innate immune, and inflammatory response and enhanced orbital adipogenesis.
TIMD4, DEFA1, DEFA1B, and DEFA3 genes may be involved in the innate immune-mediated
orbital inflammation in TO. Epigenetic mechanisms may play a role in the pathogenesis of TO.
Keywords: gene expression profiling, cDNA microarray, thyroid ophthalmopathy, Graves’
orbitopathy
Thyroid orbitopathy (TO) is an autoimmune disorder of theorbit related to Graves’ disease. Thyroid orbitopathy occurs
in 25% to 50% of patients with Graves’ disease, and 3% to 5%
present with potentially blinding complications such as optic
nerve compression or exposure keratopathy.1 Extraocular
muscle enlargement from glycosaminoglycan deposition and
interstitial swelling, connective tissue inflammation, and orbital
fat expansion are part of the observed pathologic process,
which leads to periocular edema, proptosis, epiphora, retro-
orbital pain, and diplopia.2–5 The molecular mechanisms
involved in orbital fat tissue expansion remains incompletely
understood. Previous microarray studies suggested peroxisome
proliferator activated receptor gamma, secreted frizzled-related
proteins, adipocyte-related immediate early genes, and lyso-
some-related genes may play a role in orbital adipogenesis.6–9
Expression microarray profiling uses high throughput
technology to generate extensive gene expression data from
small amounts of tissue. It is a rapid and highly effective way to
discover differentially expressed genes with high sensitivity,
thus advancing the understanding of pathogenesis without
biases from prior knowledge of the disease. We aimed to
determine differentially expressed genes that may be involved
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in stimulating orbital inflammation and orbital adipose tissue
expansion in TO using microarray gene expression profiling in
a case-control study to improve understanding of the molecular
processes involved in this disease.
METHODS
Tissue Samples
Human orbital fat samples were obtained during orbital
decompression (extraconal orbital fat) and upper lid surgeries
(preaponeurotic orbital fat) in patients with TO. Patients with
TO were subclassified as active (n ¼ 12) or inactive (n ¼ 21).
Normal controls (n ¼ 21) were patients without autoimmune
thyroid disease with adipose tissue harvested from corre-
sponding anatomical locations at the time of unrelated orbital
and lid surgeries. Thyroid orbitopathy status was determined
by an ophthalmologist according to vision, inflammation,
strabismus, appearance (VISA) classification.10 Active TO is
defined by the presence of signs of orbital inflammation;
inactive TO was defined by the absence of these inflammatory
signs. Activity of thyroid eye disease was defined by
inflammatory index score; the maximum inflammatory index
score is 8, where chemosis could score up to 2, conjunctival
redness up to 1, lid erythema up to 1, lid edema up to 2, and
retrobulbar pain up to 2 points. Seventy-five percent of active
TO and 76% of inactive TO are euthyroid, 25% of TO patients
had subclinical hyper- or hypothyroidism while on medical
treatment, but there was no statistically significant difference
in the means of TSH and T4 levels. The research was
conducted in compliance with the Declaration of Helsinki
and was approved by human research ethics committee of the
Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Following excision, orbital adipose tissue was immediately
immersed in RNAlater solution (Ambion, Austin, TX, USA). The
specimens were stored at 48C for at least 24 hours before long-
term storage at 808C.
RNA Extraction and Hybridization to Microarrays
Total RNA was extracted using RNeasy microarray tissue Mini
Kit 50 (Qiagen, Valencia, CA, USA) according to the
manufacturer’s protocol. The quality and quantity of RNA
was ascertained on a Bioanalyzer 2100 (Agilent Technologies,
Inc., Santa Clara, CA, USA) using NanoChip according to
manufacturer’s protocol. The mean RNA Integrity Number
(RIN) for the RNA samples was 6.92 6 0.7 SD. RNA samples
were processed and hybridized to microarrays in two batches 1
year apart at the Australian Genome Research Facility using
Illumina TotalPrep RNA Amplification Kit (Life Technologies,
Carlsbad, CA, USA) protocol. A total of 750 ng amplified RNA
was prepared for hybridization to HumanHT-12 v4 Expression
Beadchip (Illumina, San Diego, CA, USA) by preparing a probe
cocktail (biotin labeled cRNA at 0.05 lg/lL) that includes GEX-
HYB Hybridization Buffer supplied with the beadchip. A total
hybridization volume of 15 lL for each sample was loaded into
a single array on the beadchip, then hybridized at 588C for 16
hours and coupled with Cy3 for scanning in the Illumina iScan
Reader. Raw intensity values for both regular and control
probes were exported to text files using Illumina GenomeStu-
dio software.
Microarray Data Analysis
Bioinformatics analysis was conducted using the limma
software package.11 The raw intensity values were background
corrected and normalized using the neqc function, which
performs ‘‘normexp’’ background correction and quantile
normalization using parameters estimated from the control
probes.12 One probe (targeting long intergenic nonprotein
coding RNA 1239) was removed because it was available only
in the batch 2 files. The proportion of probes expressed in
each sample was estimated using the propexpr function,
which compares regular probes to negative controls.13 The
average proportion of expressed probes was found to be
53.6%, so the top 53.6% probes with highest average log
normalized expression values were retained for subsequent
analysis. This left 25,796 probes. The Illumina manifest file
(HumanHT-12_V4_0_R2_15002873_B) was used to associate
an Entrez Gene identifier with each probe. Other gene
annotation was obtained from the National Center for
Biotechnology Information Homo sapiens gene information
file downloaded on November 21, 2013.
Linear models were used to test for expression differences
between disease categories while adjusting for sex differences
and for differences between the hybridization batches. The
correlation between repeated measurements from the same
patient was estimated as 0.4 and incorporated into the linear
models.14 Empirical array quality weights were estimated to
allow for differences in quality between the RNA samples.15
Differential expression between active TO, inactive TO, and
normal tissue was assessed using empirical Bayes moderated t-
statistics,16 allowing for an intensity-dependent trend in the
standard errors. The false discovery rate (FDR) was controlled
at less than 0.05 using the Benjamini and Hochberg method.
Genes associated with the inflammatory index score were
identified the same way, except that the quantitative index
score was used in the linear model instead of the disease
categories.
Molecular signature enrichment analyses were conducted
using limma’s mroast function,17 which uses residual rotation
to conduct gene set tests. Roast was run with 99,999 rotations,
using the same linear model settings as for the differential
expression analysis including batch correction, patient corre-
lations, and quality weights. Gene sets representing expression
signatures were downloaded from the c2-curated collection of
Version 4.0 of the Molecular Signatures Database.18
The lists of differentially expressed genes were uploaded to
DAVID 6.7 webtool,19,20 to test for overrepresentation of
pathways from the Biological Biochemical Image Database
(BBID), BioCarta, and Kyoto Encyclopedia of Genes and
Genomes (KEGG) databases.
Quantitative Reverse Transcription–Polymerase
Chain Reaction (qRT-PCR) Validation
A total of eight active, 13 inactive TO, and 11 normal control
orbital adipose samples, with RNA extracted as above, were
used to confirm findings. This included three active TO, five
inactive TO, and three normal controls also used in the
microarray study. All RNA samples underwent in-solution
DNase digestion using RNAse-Free DNase Set (Qiagen)
followed by on-column RNA cleanup using RNeasy Mini Kit
(Qiagen). The mean RIN for these RNA samples was 6.72 6
0.35 SD.
Quantitative RT-PCR was performed in a 384-well plate with
19 gene targets chosen from the top ranked and some lower
ranked genes of interest. Expression levels of SREBF1, TIMD4,
DEFA3, DEFA1B, DEFA1, FADS1, SCD, ELOVL6, DYNCII1,
PLOD2, CHDH, LTB, CD3D, CAMP, EOMES, CD8A, CCL5,
GZMA, and SLAMF6 were compared in duplicate. cDNA
synthesis was performed using RT2 First strand Kit, and cDNA
amplification was performed using RT2 SYBR Green qPCR
Mastermix in an Applied Biosystems viiA 7 (Life Technologies,
Carlsbad, CA, USA) thermal cycler according to RT2 Profiler
PCR Array protocol (Qiagen) according to MIQE guidelines.21
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Fold change and P values were analyzed using the web-based
resource GeneGlobe Data Analysis developed by SABioscience
(http://www.sabiosciences.com/pcrarraydataanalysis.php; pro-
vided in the public domain by SABioscience, a Qiagen
company).
RESULTS
The study was designed to determine the differences in genes
expression profiles in TO by comparing diseased orbital
adipose tissue when TO is in the active and inactive phases,
and by comparing active TO with normal healthy tissues in a
case-control study design. Orbital adipose tissue samples were
harvested during orbital decompression and preaponeurotic
orbital fat during eyelid surgeries in TO cases. Orbital fat from
corresponding anatomical positions was harvested from
unaffected healthy controls. TO status was determined by an
ophthalmologist based on grading of vision, signs of orbital
inflammation, strabismus and ocular motility, and severity of
appearance according to VISA classification.10 Active TO is
defined by presence of signs of orbital inflammation including
periocular edema, lid erythema, conjunctival chemosis, and
injection; inactive TO defined by the absence of these
inflammatory signs.
Differentially Expressed Genes Between Active
and Inactive TO Identified by Microarray Analysis
The Illumina HumanHT-12 v4 contains 47,323 probes. Overall,
the average proportion of expressed probes was 53.6%, hence
the top 53.6% probes equivalent to 25,796 probes were
retained for analysis. Seven hundred twenty-one probes (355
up and 366 downregulated) representing 683 annotated genes
were significantly differentially expressed in the active TO
versus inactive TO samples (FDR < 0.05). The top differentially
expressed genes were dominated by overexpressed cell-
mediated and innate immune response genes and adipogenesis
markers (Table 1). Twenty of the 40 top differentially
expressed probes represented immune and inflammatory
response genes. Of these, 19 were upregulated and one was
downregulated. TIMD4 was overexpressed by 4.20-fold and
DEFA3 by 4.14-fold. DEFA1B was represented by three
different probes and was upregulated by 3.05- to 4.04-fold
and DEFA 1 by 3.95-fold. Genes overexpressed by 1.5- to 2-fold
were CST7, CD247, NKG7, PTPRCAP, EOMES, GZMA, CYTL1,
SLAMF6, KLRG1, CCL5, and CAMP. MASP1, a C4/C2 activating
component of Ra-reactive factor, was significantly downregu-
lated. Markers of adipogenesis were overexpressed by 2.36- to
6.12-fold including FADS1, SCD, and SCDP1. Lipid synthesis
regulatory genes SREBF1 and DBI were upregulated by 1.40-
and 1.52-fold, respectively. FZD9 was downregulated by 1.50-
fold, whereas GPX3 was upregulated by 1.83-fold.
Differentially Expressed Genes Between Active TO
and Normal Controls Identified by Microarray
Analysis
Of the 25,796 expressed probes, 806 probes (429 up- and 377
downregulated) representing 735 genes were differentially
expressed in active TO compared to normal controls (FDR <
0.05). Ten of the 40 top ranked probes were from genes
involved in adipogenesis, specifically unsaturated fatty acid and
cholesterol synthesis including SREBF1, SCD, SCDP1, FADS1,
PTPLB, and ACSS2; these genes were upregulated by 1.57- to
5.37-fold (Table 2). Differential expression of other genes
involved in metabolism included upregulation of PDXK and
downregulation of CHDH. Eight of the top 40 ranked
differentially expressed probes were from genes involved in
cytoskeleton organization, collagen binding, cellular adhesion,
and migration. Upregulated genes were PLOD2, HOOK2, and
SYNC with a fold difference of 1.45 to 1.91. Downregulated
genes were FNDC5, DYNC1I1, TMSB15B, COLGALT2, and
RADIL with fold change ranging from 1.51 to 2.10. Five
immune and inflammatory response genes, TIMD4, KLRG1,
DEFA3, PTGER3, CST7, were upregulated by 1.51 to 3.70-fold.
Two genes coding protein with zinc binding domain
(PDZRN4) and ubiquitin-protein ligase activity (TRIM9) were
downregulated, and the specific functions of these genes have
not been determined.
Correlation of Differential Expressed Genes With
Inflammatory Index Score
To explore the effects of more graduated changes in orbital
inflammation, we directly correlated the expression of each
gene with the individual inflammation index scores instead of
categorizing patients into normal, active TO, and inactive TO.
This analysis detected 188 probes positively correlated with
inflammation and 162 negatively correlated (FDR < 0.05;
Supplementary Table S1). Genes previously found to be
upregulated in active TO were generally found to be positively
correlated with inflammation, while those previously found to
be downregulated in active TO were negatively correlated.
Supplementary Table S2 shows correlation results for selected
top ranking genes from the disease comparisons including all
19 genes selected for PCR validation. These results confirm
negative correlations for CHDH and DYNC1I1 and positive
correlations for the other genes.
Validation of Differential Expression of Genes in
Orbital Adipose Tissue Specimens
Seventeen and eight gene targets were chosen for validation
from the active versus inactive and active versus normal
comparisons, respectively. Quantitative RT-PCR was used to
analyze the expression of these genes in eight active TO, 13
inactive TO, and 11 normal control orbital adipose samples.
The qRT-PCR results were closely correlated with the micro-
array results, with all log 2-fold changes of comparable size and
in the same direction as the microarray results for the same
genes. This was true both for the active versus inactive TO
comparison (Table 3) and for the active TO versus normal
comparison (Table 4). Most chosen genes were confirmed to
be significantly differentially expressed in the validation
samples; even those genes that failed to achieve statistical
significance still showed expression changes of similar size and
direction to the microarray results.
Gene Set Enrichment Analysis (GSEA) of Molecular
Signatures
To understand the active TO expression profile more deeply,
we conducted a GSEA using curated signatures from the
Molecular Signatures Database.18 Each signature was tested
using rotation gene set tests (ROAST),17 which are able to
adjust for sex differences, patient effects, and batch effects.
A number of epigenetic signatures were found significantly
dysregulated in active TO, both in comparing to inactive TO
and normal control. Upregulated hypomethylation of gene
clusters in immunodeficiency signaling, cytotoxic T-cell
mediated apoptosis and T-cell receptor, and hypomethylation
of gene cluster representing epigenetic signature of PML-RARA
leukemia (Figueroa AML methylation cluster 5 and cluster 6)
were noted in active compared to inactive TO. Conversely,
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TABLE 1. Top 40 Differentially Expressed Gene Probes in Orbital Adipose Tissue in Active Versus Inactive TO
Illumina Probe
Identifier
Gene
Symbol logFC* AveExpr† P Value FDR‡ Gene Functions
4850332 TIMD4 2.07 5.43 2.20 3 1011 5.66 3 1007 Phagocytosis of apoptotic cell, immune tolerance
4810341 CST7 0.71 5.76 1.79 3 1009 2.12 3 1005 Cysteine endopeptidase inhibitor,
immune response
4850195 SCDP1 2.61 6.72 2.46 3 1009 2.12 3 1005 Unknown
2360020 FADS1 1.38 8.48 5.61 3 1009 2.40 3 1005 Unsaturated fatty acid biosynthetic process
6290400 CD247 0.80 7.03 5.71 3 1009 2.40 3 1005 T-cell receptor complex and signaling
2970747 DEFA3 2.05 5.22 6.12 3 1009 2.40 3 1005 Innate immune response, cell killing
2450427 NKG7 0.86 7.23 6.68 3 1009 2.40 3 1005 Protein binding, plasma membrane component
4860128 DEFA1B 2.02 5.42 1.01 3 1008 2.87 3 1005 Innate immune response, cell killing, chemotaxis
870477 DEFA1B 1.75 5.13 1.11 3 1008 2.87 3 1005 Innate immune response, cell killing, chemotaxis
3890689 CD247 0.74 7.05 1.57 3 1008 3.69 3 10-05 T-cell costimulation, innate immune response
4230521 SREBF1 0.49 4.64 2.44 3 1008 5.14 3 1005 Regulation of fatty acid and cholesterol
metabolic process
7150170 DEFA1B 1.61 5.12 2.59 3 1008 5.14 3 1005 Innate immune response, cell killing, chemotaxis
5490019 GPX3 0.87 11.23 2.86 3 1008 5.28 3 1005 Oxidation-reduction, response to reactive
oxygen species, selenium binding
1430341 PTPRCAP 0.77 5.13 5.62 3 1008 9.66 3 1005 Defence response, positive regulator of CD45
7320372 EOMES 0.88 6.07 6.52 3 1008 0.0001 Positive regulation of T-cell differentiation
60324 OCRL 0.27 9.04 7.51 3 1008 0.0001 Phospholipid metabolic process
3420612 GZMA 0.81 7.44 8.18 3 1008 0.0001 Apoptosis process, cytolysis, immune response
670731 CYTL1 0.92 6.22 8.75 3 1008 0.0001 Positive regulation of transcription factors,
receptor binding
5910491 GPC5 0.78 4.85 1.02 3 1007 0.0001 Retinoid, glycosaminoglycan metabolic process
6760706 MCOLN3 0.68 5.16 1.34 3 1007 0.0002 Ion transmembrane transport, locomotory
4050326 MASP1 0.80 5.03 1.36 3 1007 0.0002 Proteolysis, complement activation, innate
immune response
7200743 SLAMF6 0.85 6.32 1.83 3 1007 0.0002 Receptor activity of CD2 subfamily
7210682 ACAP1 0.80 5.31 1.86 3 1007 0.0002 GTPase activator activity, protein transport
3520762 DYNC1I1 0.60 6.04 2.07 3 1007 0.0002 Vesicle transport along microtubule
4280131 BTC 0.80 5.29 2.09 3 1007 0.0002 Phosphatidylinositol-mediated signaling,
growth factors receptor signaling pathway
4880193 KLRG1 0.61 6.18 2.56 3 1007 0.0002 Innate immune response, inflammatory response
4780678 ZAP70 0.40 4.68 2.90 3 1007 0.0003 T-cell receptor signaling, T-cell activation,
differentiation, and migration
240400 PMEPA1 0.50 9.69 3.06 3 1007 0.0003 TGFb receptor signaling pathway, negative
regulator of SMAD protein
620717 CCL5 0.85 7.60 3.90 3 1007 0.0003 Macrophage, T cell, NK cell chemotaxis,
chemokine-mediated signaling, inflammatory
response, leukocyte cell–cell adhesion
2140128 SCD 1.24 11.98 4.54 3 1007 0.0004 Fatty acid biosynthetic process, stearoyl-CoA
9-desaturase activity
4540239 DEFA1 1.98 5.75 4.59 3 1007 0.0004 Defense response, innate immune, cell killing
4200259 ACLY 0.48 9.99 6.20 3 1007 0.0005 Lipid biosynthetic process
6200132 FZD9 0.59 5.69 6.28 3 1007 0.0005 Wnt signaling pathway
6450482 IL20RA 0.67 5.77 7.35 3 1007 0.0005 IL-20 binding, intrinsic apoptotic signaling
1230731 NFXL1 0.39 6.99 7.50 3 1007 0.0005 Negative regulation of RNA polymerase II
transcription
6840044 SREBF1 0.79 7.69 7.91 3 1007 0.0006 Lipid biosynthesis process, insulin receptor
signaling pathway
2480338 DBI 0.60 9.25 8.23 3 1007 0.0006 Trygylceride metabolic process, benzodiazepine
receptor binding
5860075 CAMP 0.89 4.74 8.97 3 1007 0.0006 Cellular response to TNF, IL-1, IL-6
4540184 SYTL4 0.58 7.50 9.34 3 1007 0.0006 Zinc ion, Rab GTPase, phopholipid, calcium ion,
neurexin protein, syntaxin, clathrin binding
7560100 NUDT11 0.50 5.63 1.03 3 1006 0.0007 Inositol phosphate metabolic process
* LogFC is log 2-fold change; hence, 1¼ 2-fold, 2 ¼ 4-fold, 3¼ 8-fold.
† AveExpr is average log2 expression.
‡ False discovery rate (FDR) < 0.05 is significant.
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TABLE 2. Top 40 Differentially Expressed Gene Probes in Orbital Adipose Tissue in Active TO Versus Normal Controls
Illumina Probe
Identifier
Gene
Symbol logFC* AveExpr† P Value FDR‡ Gene Functions
4640187 PLOD2 0.87 7.30 1.63 3 1008 0.0002 Oxidation-reduction, response to hypoxia,
extracellular matrix organization
3390343 SREBF1 0.93 9.30 2.23 3 1008 0.0002 Regulates fatty acid and cholesterol
metabolism
3390739 FNDC5 1.07 6.34 2.82 3 1008 0.0002 Positive regulation of brown fat cell differentiation
3520762 DYNC1I1 0.74 6.04 3.46 3 1008 0.0002 Vesicle transport along microtubule
5910433 CHDH 0.72 5.18 3.48 3 1008 0.0002 Choline dehydrogenase activity
6420240 PDZRN4 1.37 5.42 5.67 3 1008 0.0002 Protein ubiquitination, zinc ion binding
6840044 SREBF1 0.99 7.69 6.57 3 1008 0.0002 Regulate lipid metabolic process
3310273 TCEAL7 0.88 6.49 8.31 3 1008 0.0002 Negatively regulate NF-jb transcription factor
7040477 PLOD2 0.53 10.28 9.29 3 1008 0.0002 Oxidation-reduction, response to hypoxia,
extracellular matrix organization
1710520 HOOK2 0.93 9.02 1.16 3 1007 0.0002 Endosome organization, protein transport
2360020 FADS1 1.40 8.48 1.17 3 1007 0.0002 Unsaturated fatty acid biosynthesis
127435 PODN 0.55 11.32 2.66 3 1007 0.0005 Negative regulation of cell proliferation and
migration
2949 GSTM5 0.93 7.93 2.75 3 1007 0.0005 Glutathione transferase activity
8566 PDXK 0.57 10.65 3.35 3 1007 0.0005 Pyridoxal phasphate biosynthetic process
645313 SCDP1 2.42 6.72 4.15 3 1007 0.0006 Unknown
70270 TMSB15B 0.59 6.35 5.52 3 1007 0.0007 Actin filament organization
460121 TRIM9 0.61 4.91 6.34 3 1007 0.0008 Protein ubiquitination
4850332 TIMD4 1.61 5.43 6.85 3 1007 0.0008 Cell membrane receptor for phosphatidyl serine
4880193 KLRG1 0.67 6.18 7.07 3 1007 0.0008 Regulation of immune response, innate
immune response, inflammatory response
1660551 SLC5A3 0.67 5.38 7.21 3 1007 0.0008 Inositol metabolic process, sodium transport
60324 OCRL 0.28 9.04 8.88 3 1007 0.001 Phopholipid metabolism, regulates GTPase
2970747 DEFA3 1.89 5.22 9.55 3 1007 0.001 Innate immune response, cell killing
4390382 GSE1 0.48 9.03 9.79 3 1007 0.001 Protein binding
240400 PMEPA1 0.54 9.69 1.00 3 1006 0.001 TGFb signaling pathway, negative regulation
of SMAD protein complex assembly
7400291 TM4SF18 0.78 7.45 1.07 3 1006 0.001 Integral component of membrane
1410240 EDN3 0.88 4.83 1.11 3 1006 0.001 Neuron differentiation, regulation of cell
proiferation and vasoconstriction, leukocyte
chemotaxis, positive regulation of MAP kinase
5220452 SYNC 0.59 8.25 1.16 3 1006 0.001 Intermediate filament-based process
4560270 PTPLB 0.65 10.10 1.25 3 1006 0.001 Fatty acid elongation, sphingolipid
biosynthesis
460338 PLOD2 0.83 5.62 1.60 3 1006 0.001 Oxidation-reduction, response to hypoxia,
extracellular matrix organization
1010110 TMEM9 0.38 7.98 1.66 3 1006 0.001 Lysosome and late endosome membrane,
transport
4490524 ACSS2 0.73 11.05 1.75 3 1006 0.001 Acetate, propionate, acetyl-CoA biosynthesis
2680441 PTGER3 0.74 6.85 1.82 3 1006 0.001 Adenylate cyclase and phospholipase G
protein coupled receptor signaling
pathway, prostaglandin E receptor activity
6980253 PTPLB 0.56 10.59 1.85 3 1006 0.001 Fatty acid elongation, sphingolipid
biosynthesis
4230521 SREBF1 0.46 4.64 1.96 3 1006 0.001 Positve regulation of RNA polymerase II
transcription, histone deacetylation
6290142 SCD 1.31 11.98 1.98 3 1006 0.001 Fatty acid biosynthesis, oxidation-reduction
2140128 COLGALT2 0.89 5.68 1.99 3 1006 0.001 Extracellular matrix organization
6840600 RADIL 0.82 6.93 2.11 3 1006 0.001 Substrate adhesion-dependent cell spreading,
microtubule
4670544 ACSS2 0.73 11.21 2.29 3 1006 0.001 Acetate, propionate, acetyl-CoA biosynthesis
4180008 TRPC1 0.51 8.15 2.31 3 1006 0.001 Ion transmembrane transport
4810341 CST7 0.60 5.76 2.42 3 1006 0.001 Cysteine endopeptidase inhibitor, immune response
* LogFC is log 2-fold change; hence, 1¼ 2-fold, 2 ¼ 4-fold, 3¼ 8-fold.
† AveExpr is average log2 expression.
‡ FDR < 0.05 is significant.
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active TO compared to normal showed negative correlation
with unmethylated histone H3 in genes with high-CpG-density
promoters (HCP) in embryonic fibroblast, downregulation of
histone H3 dimethylation at K4 and trimethylation at K27 in
brain, and downregulation of genes methylated aberrantly in
colon cancer cells (Supplementary Tables S3, S4).
Active TO versus inactive TO was characterized by
upregulation of cell adhesion and cytoskeleton organization
pathways including stathmin, cell-to-cell, E-cadherin nascent
adhesion junction, and e-cadherin stabilization pathway.
Molecular processes for activation of T cell (CSK, TOB1, T-
cell receptor activation pathways), cytotoxic T cell (down-
stream CD8 T cell, cytotoxic T-cell pathway), T helper cell
function, IL-12 dependent Th1 development, Th1 specific
genes and natural killer cell response, and immunoregulation
in lymphoid cells were upregulated in active versus inactive
TO. Interestingly, CD40 signaling was negatively correlated
with active TO. Gene sets controlling cell proliferation and cell
cycling were downregulated as exemplified by downregulation
of ERBB network, nuclear ERBB4 signaling, but genes involved
in mitogen-activated protein kinases (MAPK) signaling, neuro-
nal proliferation, and differentiation were upregulated. Apo-
ptosis was regulated by upregulation of caspase cascade and
upregulation of genes negatively correlated with telomere
shortening and telomerase reverse transcriptase, respectively.
Lymphogenesis associated genes were upregulated. Multiple
oncogenic genes, tumor suppressor genes, and homeobox
genes were dysregulated in active TO in the context of
comparing with cancer gene expression profiles
(Supplementary Table S3).
Analysis of the active TO versus normal control expression
changes revealed correlation with a number of signatures
regulating lipid metabolism. These include genes involved in
lipid digestion, mobilization and transport, integration of
energy and metabolism, SREBF and peroxisome proliferator-
activated receptor (PPAR) targets, the WNT noncanonical
pathway, and biosynthesis of unsaturated fatty acids. Cytoskel-
eton control stathmin pathway was upregulated. Apoptosis
pathways were upregulated with increased proportion of
genes in caspase cascade, upregulation of proapoptotic genes
regulated by telomerase reverse transcriptase, camptothecin,
and methotrexate. Cell cycling was downregulated with
downregulation of genes involved in activation of prereplica-
tive complex and Rad3-related kinase (ATR), G2 checkpoint in
mitosis, and mini-chromosome maintenance pathway, whereas
cell differentiation was upregulated (osteoblast differentiation
in response to phenylamil). Genes related to hypoxia were
upregulated. Generally, cancer-related gene profiles are down-
regulated in active TO compared to normal (Supplementary
Table S4).
Pathway Analysis Using DAVID Functional
Annotation Analysis
Functional annotation was examined more systematically for
the entire set of differentially expressed genes by using the
DAVID tool.19,20 Analysis of differentially expressed genes for
the active versus inactive TO comparison revealed overrepre-
sentation of the following pathways: KEGG’s regulation of
actin cytoskeleton (17 genes, P ¼ 2.9 3 103), adherens
junction (eight genes, P¼ 0.017), glycolysis (seven genes, P¼
0.017), MAPK signaling (17 genes, P ¼ 0.022), glutathione
metabolism (six genes, P¼ 0.028), biosynthesis of unsaturated
fatty acids (four genes, P¼ 0.039), focal adhesion (13 genes, P
¼ 0.045); BioCarta’s T cytotoxic cell surface molecules (five
genes, P ¼ 1.7 3 103), Lck and Fyn tyrosine kinases in
initiation of TCR activation (four genes, P ¼ 0.013), T-helper
cell surface molecules (four genes, P ¼ 0.016), CTL-mediated
immune response against target cells (four genes, P ¼ 0.031),
and IL-17 signaling pathway (four genes, P ¼ 0.031).
Functional annotation of differentially expressed genes in
active TO versus normal controls highlighted overrepresented
molecular pathways involved in KEGG’s PPAR signaling (13
genes, P ¼ 5.6 3 106), citrate cycle (seven genes, P ¼ 7.6 3
104), biosynthesis of unsaturated fatty acids (six genes, P¼9.8
3 104), insulin signaling (13 genes, P ¼ 3.6 3 103), focal
adhesion (16 genes, P¼6.43103), butanoate metabolism (six
genes, P ¼ 7.3 3 103), pentose phosphate (five genes, P ¼
TABLE 3. Validation of Differential Express of Genes in Active Versus
Inactive TO by qRT-PCR
Gene
Targets
Fold
Change* P Value
Log FC
PCR†
Log FC
Microarray‡
FADS1 2.85 0.0001 1.51 1.38
ELOVL6§ 3.96 0.0004 1.99 0.93–1.10
CAMP 3.15 0.0004 1.66 0.89
SCD 7.84 0.001 2.97 1.24
TIMD4 9.61 0.004 3.26 2.07
EOMES 1.89 0.01 0.92 0.88
CD8A§ 2.57 0.01 1.36 0.68–0.88
GZMA 2.29 0.01 1.20 0.81
SREBF1 1.37 0.01 0.45 0.49–0.79
DEFA1B 2.49 0.03 1.32 1.61–2.02
CD3D§ 2.55 0.03 1.35 0.96
SLAMF6 2.39 0.03 1.26 0.85
DEFA3 2.75 0.04 1.46 2.05
DEFA1 3.03 0.04 1.60 1.98
LTB§ 2.18 0.05 1.12 0.52–1.04
DYNC1I1 0.83 0.06 0.27 0.60
CCL5 1.74 0.09 0.80 0.71–0.85
Columns 2 through 4 give PCR results while column 5 shows
corresponding microarray results.
* Fold change values greater than 1 indicate an upregulation, and
values less than 1 indicate downregulation.
† Log FC PCR is log 2-fold change from qRT-PCR.
‡ Log FC is log 2-fold change from microarray analysis. Range in
LogFC microarray relates to LogFC of more than one probe for the
gene.
§ Differentially expressed genes of lower ranks from microarray
study (below top 40) still validated by qRT-PCR.
TABLE 4. Validation of Differentially Expressed Genes in Active TO
Versus Normal Healthy Control by qRT-PCR
Gene
Targets
Fold
Change* P Value
Log FC
PCR†
Log FC
Microarray‡
SREBF1 1.61 0.005 0.69 0.46–1.00
SCD 4.22 0.005 2.08 1.31
FADS1 2.28 0.006 1.19 1.40
CHDH 0.50 0.008 1 0.72
DYNC1I1 0.84 0.08 0.25 0.74
TIMD4 4.99 0.09 2.32 1.61
DEFA3 1.26 0.12 0.33 0.48
PLOD2 1.19 0.52 0.25 0.53–0.87
Columns 2 through 4 give PCR results while column 5 shows
corresponding microarray results.
* Fold change values greater than one indicate an upregulation, and
values less than one indicate downregulation.
† Log FC PCR is log 2-fold change from qRT-PCR.
‡ Log FC is log 2-fold change from microarray analysis. Range in
LogFC microarray relates to LogFC of more than one probe for the
gene.
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0.012), glycerolipid metabolism (six genes, P ¼ 0.023), and
glutathione metabolism (six genes, P ¼ 0.035).
Pathways for regulation of actin cytoskeleton, adherens
junction, MAPK signaling, Lck and Fyn tyrosine kinases in
initiation of TCR activation, PPAR signaling, and insulin
signaling pathways are illustrated in Supplementary Figures
S1 through S6 with arrows pointing up for upregulated and
down for downregulated gene probes. The corresponding
Supplementary Tables S5 through S10 correlates dysregulated
gene probes with the coded proteins shown on the illustrated
pathways, and showed extent of gene probe dysregulation.
DISCUSSION
This differential gene expression profiling study utilizes the
largest number to date of orbital adipose tissues in TO patients
and normal subjects. This is the first gene profiling study to
compare TO in early and late phases and uses high density
Illumina microarray platform to derive meaningful findings.
The high throughput technology combined with selection of
phenotypically well-characterized TO patients generated ex-
tensive gene expression data, which allowed examination of
differentially expressed genes with high sensitivity. The results
were validated by qRT-PCR. Functional annotation of genes
showed good correlation between different bioinformatics
analysis.
The principal finding of this study is that cell-mediated and
innate immune response genes and adipogenesis markers are
concurrently overexpressed in active TO, and epigenetic
pathways may be involved in the pathogenesis of TO. Among
these, TIMD4, DEFA3, DEFA 1, and DEFA1B were highly
overexpressed. T-cell immunoglobulin and mucin domain
containing 4 (TIMD4, also known as TIM4) is a cell membrane
receptor exclusively on antigen-presenting cells including
dendritic cells and macrophages that recognizes phosphatidyl
serine, a specific marker of apoptosis, and via its immunoglob-
ulin domain has a role in phagocytosis of apoptotic cells and in
immune tolerance.22,23 Blockade of TIMD4 results in increased
numbers of antigen specific T cells following the peak of
immune response. Conversely, overexpression of TIMD4 on
antigen-presenting cells resulted in decreased antigen-specific
T cells and decreased secondary T-cell response in TIMD4
transgenic mice.24 Overexpression of TIMD4 in peripheral
blood mononuclear cells was noted in patients with systemic
lupus erythematosus (SLE), especially during the active phase
of the disease compared with healthy controls. Furthermore,
TIMD4 mRNA expression positively correlated with TIM1 and
TNF-a in SLE but not in healthy controls.25
TIM1 expression in polarized human Th2 cells is known to
be upregulated in allergic rhinitis patients compared with
healthy controls. TIM4 on dendritic cells played a critical role
in maintaining skewed Th2 response by interacting with TIM1
on Th2 cells.26 We therefore hypothesize that TIMD4 is an
important immune regulator in TO. Overexpression of TIMD4
in TO may induce innate immune cells such as macrophages
and dendritic cells to phagocytose apoptotic T cells to
maintain immune balance in the context of increased
apoptotic load during the active phase of the disease. Increased
TIMD4 expression may also explain the Th2 dominance
observed in the late phase of TO.27 The hypothesis that
TIMD4 overexpression is a precursor for switching off active
orbital inflammation in TO is now worth exploring.
We report here significantly higher levels of a-defensins
(DEFA1 and DEFA3) in active TO. Thyroid orbitopathy may
share these biomarkers with other autoimmune disorders.
There is considerable evidence that a-defensins are part of the
innate immunity derived from neutrophils and monocytes.28–30
a-defensins are involved in the inflammatory response as a
chemotactic factor for neutrophils, monocytes, and T cells and
promote adaptive immune responses. Conversely, a-defensins
also reduces inflammatory injury through inhibiting lipopoly-
saccharide-mediated responses, and inhibiting proinflamma-
tory cytokine secretion by macrophages.29 The role of DEFA1-3
in the pathogenesis of autoimmune diseases such as rheuma-
toid arthritis (RA), SLE, Behc¸et’s disease, and lung diseases has
been increasingly recognized.28,29,31–33
The a-defensin-1 promotes inflammation through induction
of proinflammatory cytokines IL-6, IL-8, and matrix metal-
loproteinases, possibly through regulation of JNK and/or ERK
MAP kinases and NF-jb pathways.31 Furthermore, a-defensins
induce synthesis of mucin and chemokines including IL-8, TNF-
b, and VEGF in lung epithelial cells and lung fibroblasts
cultures.28 Even though a-defensins are mainly expressed by
neutrophils, other studies suggest that T lymphocytes, NK
cells, and monocytes also produce DEFA1-3. DEFA1-3 are
known to be significantly higher in T cells from peripheral
blood and blister fluid in Stevens-Johnson syndrome/toxic
epidermal necrolysis patients, where cytotoxic T cells are the
main effector cells.30
Our study confirms findings of previous microarray and cell
culture studies that increased adipogenesis occur in active
TO.6,34,35 A group of genes involved in fatty acid and
cholesterol synthesis was upregulated in our study including
SREBF1, SCD, FADS1, and SCDP1. Gene sets enriched in lipid
metabolism, including biosynthesis of unsaturated fatty acids,
fatty acyl-CoA synthesis, triacylglycerol and ketone body
metabolism, glycolysis pathway, and integration of energy
metabolism, were upregulated. In addition, pathway analysis
showed overrepresentation of pathways linked to adipogenesis
including PPAR activation, insulin signaling pathway, unsatu-
rated fatty acid synthesis, and glycerolipid metabolism.
The overexpression of SCD in TO orbital fat tissue
compared with normal controls was independently validated
by Lantz et al.,7 who further linked overexpression of
immediate early genes in smokers with severe active TO.36
Upregulation of several adipocyte regulatory genes including
PPARc, adiponectin, and leptin support increased de novo
adipogenesis and/or fat cell expansion in TO.6 In addition,
adipogenesis may be regulated through Wnt-signaling with
dysregulation of secreted frizzled-related protein-1, Wnt5a,
sFRPs, and DKK.6,37 Our study identified frizzled family
receptor 9 (FZD9), a receptor for Wnt signaling protein,
which was modestly downregulated in active compared to
inactive TO. FZD9 was activated by Wnt-2 and functions in
Wnt/b-Catenin signaling in mice.38 However, a pathogenic role
for FZD9 in TO remains unclear as yet.
Multiple cell-mediated immune genes were overexpressed
in TO confirming the importance of cellular immunity in the
pathogenesis of TO. CD247, CD3D, CD8A, CST7, GZMA,
CAMP, SLAMF6, EOMES, LTB, and CCL5 were upregulated in
active TO compared with inactive TO. CD3d and CD247 are
components of the T-cell receptor complex, while Cd8a is a
surface molecule on cytotoxic T cells. CST7 is a member of
cysteine protease inhibitors expressed by T cells, natural killer
cells, monocytes, and mast cells.39 CST7 could be important in
regulating serine protease activity in IL-12 activated natural
killer cells by inhibiting cathepsin C.40 Granzyme A (GZMA) is
a serine protease found in cytotoxic T cells and NK cells. There
is mounting evidence that granzyme A induces caspase-
independent apoptosis in targeted cells, as well as inducing
IL-8, IL-6, and IL-1b production and facilitates lymphocyte
migration through the extracellular matrix.41 SLAMF6 encodes
a transmembrane protein of CD2 subfamily on NK cells, T and
B lymphocytes, and functions as a costimulatory molecule,
which primes T cells to produce Th1 cytokines.42 CAMP
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relates in function to defensin in antimicrobial activity, cell
chemotaxis, immune mediation, and inflammation response
regulation.29 PTPRCAP is a positive regulator of tyrosine
phosphatase PTPRC (CD45), a key regulator of T and B
lymphocytes activation.43 EOMES is a transcription factor
crucial for mesoderm and neural development and a key
regulator for differentiation of CD8þT cells.44 LTB, also known
as TNF superfamily, member 3 is proinflammatory and is
involved in normal development of lymphoid tissue.45 The
upregulation of LTB supports the notion of a role of TNF-
antagonist in the treatment of active TO.46 GPX3 functions in
detoxification of reactive oxygen species and hydrogen
peroxide that involves selenium binding at its active site
(http://www.ncbi.nlm.nih.gov/gene/2878; provided in the
public domain by the National Center for Biotechnology
Information, Bethesda, MD, USA). The upregulation of GPX3
in active TO may explain the observations that selenium
supplementation helps with soft tissue signs in active TO, and
the relative selenium deficiency in TO cases.47,48 Of note,
targets for novel and experimental therapies for TO including
CD-20, IL-1, IL-6, IL-8, and IGF-1R were not differentially
expressed in the orbital adipose tissue that we studied, and
TSHR was low ranking and marginally downregulated in active
TO compared to inactive TO (data not shown).
CCL5, also known as RANTES, is an important chemo-
attractant for blood monocytes, T-helper cells, and eosinophils.
Immunoglobulins from Graves’ disease patients induced
increased expression of RANTES in TO orbital fibroblast.49
The GSEA and pathway analysis are in keeping with
translational studies highlighting the Th1 cytokine expression
profile, T-cell recruitment, and activation by orbital fibroblasts,
dysregulation of MAPK signaling, infiltration of lymphocytes,
macrophages, and monocytes in TO affected orbital tissues on
histology.5,49–53
Our study revealed epigenetic factors may play a role in
pathogenesis of TO. Active TO displayed gene set enriched
with epigenetic signatures of acute myeloid leukemia (AML).
Hypermethylation of DNA leads to silencing of genes,
conversely aberrant hypomethylation of cluster 5 epigenetic
markers in AML relates to dysregulation of immunity-related
pathways involving immune deficiency signaling, cytotoxic T-
cell mediated apoptosis, and T-cell receptor signaling.54 Active
TO also showed downregulation of genes with unmethylated
histone 3 in high CpG density promoters (HCP). Methylation at
K4 (H3K4me3) and K27 (H3K27me33) on histone 3, known as
bivalent status on HCP is associated with cell lineage
commitment, genes related to adipogenesis (PPARc) often
remains bivalent in differentiating embryonic fibroblast.55
Gene sets enriched with T cell-mediated immune response
include T-cell receptor signaling via COOH-terminal Srk kinase
(CSK), Lck and Fyn tyrosine kinases, TOB1 nuclear transducer
together modulate T-cell activation, and proliferation. Gene
sets involved in IL-12 and NO2 dependent IL-12 signaling
pathways were upregulated, which induce Th1 cell differen-
tiation and activation of both T and NK cells via JAK/STAT
transcription factor signaling. Activation of T-helper cell,
cytotoxic T cell, caspase cascade, and telomere shortening
mediated immune-related apoptosis in target cells. Further
gene sets enriched in cell-to-cell adhesion signaling, stathmin,
and E-cadherin signaling mediating intercellular communica-
tion may result in changes in cytoskeleton and facilitate cell
mobility, migration, and proliferation.
One potential limitation of the interpretation of the
microarray data is that prior immunosuppressive treatment
was not factored into the analysis. Despite more active TO
cases had intravenous methylprednisolone within 2 months
prior to surgery compared to inactive TO and normal controls,
active TO cases still had signs of orbital inflammation at the
time of surgery. The microarray results still detected signifi-
cantly upregulation of genes involved in immune and
inflammatory responses and showed positive correlation of
inflammatory index score in vast majority of the top ranked
genes expressions tested. In addition, intravenous dexameth-
asone was routinely used at induction of general anesthesia for
orbital surgery in both active TO and inactive TO and normal
controls, and the prevalence of intravenous dexamethasone
use between the groups of patients was statistically insignif-
icant; hence, the differential RNA expression observed is
unlikely due to confounding steroid effects.
In conclusion, TIMD4, DEFA1, DEFA1B, and DEFA 3 were
overexpressed in active TO compared with inactive TO,
suggesting a pathogenic role of the innate immune response
in TO. Active TO was marked by upregulation of genes
involved in cell-mediated, innate, and inflammatory responses
with concurrent enhancement of orbital adipogenesis. Epige-
netic mechanisms may play a role in TO. The study gives new
insights into the underlying complex molecular mechanisms in
TO, and provides novel insights into candidate molecules and
pathways, which can be explored to develop alternative
treatment strategies for the treatment of TO, which carries
substantial visual morbidity.
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